![]() ![]() 6 Participants considered to have a relapse were offered a 3-day course of IV methylprednisolone (1 g daily) or oral equivalent at the discretion of the treating neurologist. Brain MRI scans were acquired on a 3T scanner according to a standardized protocol as described elsewhere. 6 Patients were randomized (1:1) to riluzole 50 mg twice a day or placebo, and also initiated weekly interferon-β (IFN-β)–1a IM as an add-on therapy 3 months after initiating the study drug. Participants had relapsing-remitting MS (RRMS) or a clinically isolated syndrome with less than 12 months duration, at least 2 silent T2-weighted hyperintense lesions on initial MRI, and no MS relapse or use of glucocorticosteroids within 4 weeks of baseline MRI scan. ![]() Study design, participants, and procedures.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |